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Diabetic nephropathy is the most common pathological disorder predisposing patients to end-stage 
renal disease.  Considering the increasing prevalence of type 2 diabetes mellitus worldwide,  novel 
therapeutic approaches are urgently needed.  ONO-1301 is a novel sustained-release prostacyclin analog 
that inhibits thromboxane A2 synthase.  Here we examined the therapeutic eﬀects of the intermittent 
administration of slow-release ONO-1301 (SR-ONO) on diabetic nephropathy in obese type 2 diabetes 
mice,  as well as its direct eﬀects on mesangial cells.  The subcutaneous injection of SR-ONO (3mg/kg) 
every 3 wks did not aﬀect the obesity or hyperglycemia in the db/db obese mice used as a model of 
type 2 diabetes,  but it signiﬁcantly ameliorated their albuminuria,  glomerular hypertrophy,  glomeru-
lar accumulation of type IV collagen,  and monocyte/macrophage inﬁltration,  and also the increase of 
TGF-β1,  α-smooth muscle actin (α-SMA) and MCP-1 compared to vehicle treatment.  In cultured mouse 
mesangial cells,  ONO-1301 concentration-dependently suppressed the increases in TGF-β,  type IV col-
lagen,  α-SMA,  MCP-1 and ﬁbronectin induced by high ambient glucose,  at least partly through pros-
tacyclin (PGI2) receptor-mediated signaling.  Taken together,  these results suggest the potential thera-
peutic eﬃcacy of the intermittent administration of SR-ONO against type 2 diabetic nephropathy,  
possibly through protective eﬀects on mesangial cells.
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iabetic nephropathy is a major microvascular 
complication of type 1 and type 2 diabetes.  
Given the fact that diabetic nephropathy is the most 
common etiology predisposing subjects in developed 
countries to end-stage renal disease (ESRD),  novel 
therapeutic approaches are urgently needed.  Compared 
to type 1 nephropathy,  type 2 diabetic nephropathy is 
more prevalent and has a more complex pathogenesis,  D
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involving various comorbidities such as obesity,  
hypertension and dyslipidemia.  Despite the diﬀerences 
in the underlying mechanisms of type 1 and type 2 
diabetic nephropathy,  the clinical and histological 
alterations are relatively similar,  at least in the early 
stage.  Glomerular hyperﬁltration,  glomerular hyper-
trophy and microalbuminuria are typically observed in 
the early stage of both types of diabetic nephropathy 
[1].  Subsequently,  the expansion of the extracellular 
matrix (ECM) in mesangial areas and overt proteinu-
ria are observed,  eventually leading to glomeruloscle-
rosis and ESRD [2].
　 The involvement of various factors and cytokines 
throughout the course of diabetic nephropathy,  includ-
ing the renin-angiotensin system,  protein kinase C and 
advanced glycation end-products (AGEs) has been 
reported [3,  4].  Among them,  the monocyte chemoat-
tractant protein-1 (MCP-1) and ﬁbrogenic transform-
ing growth factor (TGF)-β1 produced by mesangial 
cells in the diabetic condition are particularly impor-
tant factors in the progression of the nephropathy 
[3].  An increased expression of MCP-1 is associated 
with the inﬁltration of monocytes/macrophages into 
glomeruli,  leading to inﬂammation and increased oxi-
dative stress [5].  TGF-β1 expression causes mesan-
gial ECM production,  which possibly induces glom-
erulosclerosis [6].
　 Prostacyclin (PGI2),  a metabolite of arachidonic 
acid,  possesses vasoprotective eﬀects that includ 
antiplatelet aggregation,  vasodilation and inhibition of 
smooth muscle cell proliferation [7,  8].  ONO-1301 is 
a synthetic nonprostanoid prostacyclin agonist that 
potently inhibits TXA2 synthase [9].  ONO-1301 has 
been reported to have therapeutic eﬀects in experi-
mental models of pulmonary hypertension,  pulmonary 
ﬁbrosis and ischemic heart disease [9-11].  ONO-1301 
polymerized with poly (D,  L-lactic-co-glycolic acid) 
(PLGA) microspheres (ONO-1301MS) was developed 
as a sustained-release preparation to allow eﬀective 
circulating levels to be maintained for 3 wks after a 
single subcutaneous injection [12].
　 The therapeutic eﬀects of sustained-release ONO-
1301MS (SR-ONO) have been demonstrated in exper-
imental models of a variety of disorders,  without 
causing hypotension,  at doses up to 100mg/kg [12-
14].  The beneﬁcial eﬀect of ONO-1301 in treating 
cardiac ischemia was demonstrated to be partly medi-
ated via the upregulation of hepatocyte growth factor 
(HGF) and vascular endothelial growth factor (VEGF)-A,  
a potent pro-angiogenic factor,  via a cAMP-dependent 
pathway [11,  15].
　 Hayashi et al.  demonstrated that ONO-1301 (twice-
daily administration) had antinephritic eﬀects in a rat 
anti-GBM nephritis model by inhibiting intraglomeru-
lar leukocyte inﬁltration [16].  We also found that 
ONO-1301 had therapeutic eﬀects in a rat type 1 
diabetes model [17] and in a unilateral ureteral 
obstruction model [18].  However,  the therapeutic 
eﬀects of ONO-1301 on type 2 diabetic nephropathy,  
as well as the precise mechanism(s) involved in its 
renoprotective eﬀects have been unclear.  In the pres-
ent study,  we tested our hypothesis that SR-ONO may 
ameliorate the renal alterations in a representative 
type 2 diabetes model,  the db/db mouse,  by regulat-
ing the accumulation of the mesangial matrix,  inﬂam-
mation and oxidative stress through PGI2 (IP) recep-
tor-mediated signaling.
Materials and Methods
　 Mice. We used adult male db/db mice (BKS.
Cg-db/db Jcl; Clea Japan,  Osaka,  Japan) and their 
age-matched non-diabetic db/m littermates (BKS.
Cg-db/＋m Jcl; Clea Japan).  The mice were given 
standard pellet laboratory chow and water ad libitum.  
The experimental protocol was approved by the 
Animal Care and Use Committee,  Okayama University 
and complied with the “Guide for the Care and Use of 
Laboratory Mice” (NIH publication No.  86-23,  revised 
1985).
　 Preparation of slow-release ONO-1301 (SR- 
ONO). ONO-1301 was synthesized by ONO 
Pharmaceutical Co.  Ltd.  (Osaka,  Japan) as described 
[10,  19].  The sustained-release form of ONO-1301 
(SR-ONO) was generated by polymerizing ONO-1301 
with poly-lactic and glycolic acid (PLGA) as described 
[12,  13].  The mean particle dia of SR-ONO was 4.5
±0.3µm as determined by a laser diﬀraction particle 
size analyzer (model SALD-2100; Shimadzu,  Kyoto,  
Japan).  The release time was adjusted to 25 days,  as 
determined by measuring the residual ONO-1301 in the 
pellets by high-performance liquid chromatography 
(HPLC) [12].
　 Protocol for animal experiments. We used 
8-wk-old db/db mice,  because they develop hypergly-
cemia at 7-8 weeks of age.  The blood glucose level of 
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the 8-wk-old db/db mice was in the range of 19.4-
26.2mmol/l.  The mice were divided into 3 subgroups 
(n＝6 for each subgroup): (1) non-diabetic control 
db/m mice,  db/db mice treated with either (2) vehicle 
(PLGA polymer containing no active substance),  or (3) 
SR-ONO at a dose of 3mg/kg body weight.  The 
vehicle or SR-ONO was subcutaneously injected on the 
mouseʼs back every 3 wks.  At 8 wks after the initial 
injection of SR-ONO (when the mice were 16 wks 
old),  the mice were anesthetized via an intraperito-
neal injection of 50mg/kg body weight of pentobarbi-
tal sodium (Sigma,  St.  Louis,  MO,  USA),  they were 
sacriﬁced and their kidneys were removed.  No mice 
died before the sacriﬁce,  and no signs of any apparent 
exhaustion were observed during the experimental 
period.
　 Blood and urine examination. The blood 
glucose level was measured in tail-vein blood using a 
conventional glucometer,  and individual 24-h urine 
sample collections were performed using metabolic 
cages at 8-wks after the initial administration of 
SR-ONO.  Non-fasting blood samples were drawn from 
the retro-orbital venous plexus using heparinized 
capillary tubes under anesthesia at the time of sacri-
ﬁce.  The serum and urinary creatinine levels and 
concentrations of urinary albumin were measured by 
Okayama Medical Laboratories (OML; Kurashiki,  
Japan) using HPLC,  an enzymatic colorimetric assay 
and an enzyme-linked immunosorbent assay (ELISA),  
respectively.  The urinary albumin concentrations 
were normalized to the urinary creatinine levels,  and 
they are expressed as the urinary albumin/creatinine 
ratio (UACR).  The creatinine clearance (Ccr) was 
calculated and is expressed as ml/min.  The plasma 
levels of total cholesterol and urea nitrogen at 8 wks 
after the initial administration of SR-ONO were also 
measured by OML.  The serum levels of ONO-1301 at 
2 wks after the ﬁnal injection of vehicle or SR-ONO 
were measured by liquid chromatography tandem mass 
spectrometry assay as described [12].
　 Histological analysis. At 8 wks after the start 
of the treatment,  the kidneys were removed from the 
mice,  ﬁxed in 10ｵ buﬀered formalin and embedded in 
paraﬃn.  Sections (3-µm) were stained with periodic 
acid-Schiﬀ (PAS) for light microscopic observation 
[20].  The mean glomerular tuft volume (GV) was 
determined from the mean glomerular cross-sectional 
tuft area (GA) as described previously [21,  17].  We 
observed 20 glomeruli from each cortical area,  and 
images were taken and analyzed using the Lumina 
Vision software program (Mitani,  Fukui,  Japan) to 
determine the mean GA.  The GV was calculated as 
GV＝β/k× (GA)3/2,  with β＝1.38,  the shape coeﬃ-
cient for spheres,  and k＝1.1,  a size distribution 
coeﬃcient [21].  GV is expressed relative to the value 
of the non-diabetic control group.
　 We deﬁned the mesangial matrix index as the pro-
portion of GV occupied by the mesangial matrix,  
excluding nuclei.  The mesangial matrix areas of 20 
glomeruli in each kidney were analyzed and averaged 
as described [22].  The mesangial areas were selected 
using the Photoshop software program (Adobe 
Systems,  San Jose,  CA,  USA),  followed by analysis 
using the Lumina Vision software program.
　 Immunohistochemistry. The immuno-
histochemical studies were performed using paraﬃn-
embedded sections as described previously [23-25].  
After deparaﬃnization and rehydration,  the sections 
were incubated with 3ｵ H2O2 in methanol to inacti-
vate endogenous peroxidase.  The sections were boiled 
in citrate buﬀer (10mM citric acid and 0.05ｵ Tween 
20 [pH6.0]) for antigen retrieval.  The sections were 
then blocked with phosphate-buﬀered saline (PBS) 
containing 3ｵ bovine serum albumin (BSA) and an 
avidin/biotin Blocking Kit (Vector Laboratories,  
Burlingame,  CA,  USA),  followed by incubation with 
rat polyclonal anti-F4/80 (1 : 200 dilution,  Serotec,  
Oxford,  UK) or mouse monoclonal anti-malon dialde-
hyde (MDA; 1 : 100,  NOF Corp.,  Tokyo,  Japan) 
antibodies.  The sections were then incubated with 
biotinylated secondary antibodies (Nichirei,  Tokyo,  
Japan),  and immunoperoxidase staining was conducted 
utilizing a Vectastain ABC Elite Reagent kit (Vector 
Laboratories).  Biotinylated goat anti-rat IgG for 
F4/80 (1 : 100 dilution) was used as secondary anti-
body.  A M.O.M.TM kit (Vector Laboratories) was used 
for the staining with the mouse monoclonal anti-MDA 
antibody.  Diaminobenzidine (DAB) was used as a 
chromogen.  All slides were counterstained with hema-
toxylin.  Normal mouse or rabbit IgG was used as a 
negative control.
　 The number of glomerular F4/80＋ monocytes/
macrophages in each glomerulus was determined.  To 
evaluate the MDA-positive area,  we obtained color 
images as TIFF ﬁles and analyzed then using the 
Lumina Vision software program.  Image ﬁles (TIFF) 
3ONO-1301 and Diabetic NephropathyFebruary 2015
were opened in the gray-scale mode.  The MDA-
positive area was calculated using the following 
formula: [Ｘ (density)×positive area (µm2)]/glomer-
ular total area (µm2),  where the staining density is 
indicated by a number from 0 to 256 in the gray scale 
[17].  We examined 40 glomerular cross-sections in 
each kidney.  Histological evaluations were performed 
in a blinded fashion by 2 investigators,  and the results 
were averaged.
　 Immunofluorescence. Immunofluorescent 
staining was performed as described [23,  26].  Brieﬂy,  
frozen sections were ﬁxed in cold (－20℃) acetone 
for 10min and then air-dried.  The sections were 
blocked with 1ｵ BSA and then incubated with poly-
clonal rabbit anti-type IV collagen (1 : 100 dilution,  
Chemicon,  Billerica,  MA,  USA) for 1h.  Subsequently,  
the sections were washed three times in PBS and 
incubated with Alexa Fluor 488-labeled goat anti-
rabbit IgG (Invitrogen,  Carlsbad,  CA,  USA) for 1h.  
After three washes with PBS,  Vectashield anti-fade 
mounting medium (Vector Laboratories) was applied 
and the sections were observed by ﬂuorescence 
microscopy (BZ-Analyzer; Keyence,  Osaka,  Japan) 
and images were obtained.  Normal rabbit IgG was 
used as a negative control.  To assess the positive 
area,  we analyzed the image ﬁles (1,392×1,040 pix-
els) at ×400 magniﬁcation using the Lumina Vision 
software program.
　 Immunoblotting. Immunoblotting was per-
formed as described [23,  27,  28].  Brieﬂy,  tissues 
were homogenized in radioimmunoprecipitation assay 
buﬀer at 4℃.  After centrifugation at 14,000rpm for 
30min at 4℃,  the supernatant was collected and 
stored at －80℃ until use.  The total protein concen-
tration was determined by the DC-protein determina-
tion system (Biorad,  Hercules,  CA,  USA) using BSA 
as a standard.  The samples were processed for 
sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE),  and the proteins were electro-
transferred onto nitrocellulose membranes (Invitrogen).
　 The membranes were blocked with 5ｵ non-fat dry 
milk in 1X Tris-buﬀered saline containing 0.1ｵ 
Tween-20 for 1h,  incubated over night with polyclonal 
rabbit anti-type IV collagen (1 : 20 dilution,  Southern 
Biotech,  Birmingham,  AL,  USA),  anti-TGF-β (1 : 20 
dilution),  alpha-smooth muscle actin (α-SMA; 1 : 50 
dilution,  Chemicon),  and Armenian hamster anti-mouse 
MCP-1 (1 : 250 dilution; BioLegend,  San Diego,  CA,  
USA) antibodies at 4℃.  After incubation with horse-
radish peroxidase-labeled anti-rabbit IgG antibodies 
for TGF-β1 or anti-hamster IgG antibodies for 
MCP-1 for 1h,  we detected the signals using an 
enhanced chemiluminescence system (Amersham,  
Arlington Heights,  IL,  USA).  The membranes were 
re-probed with rabbit anti-actin antibodies (Chemicon) 
to serve as loading controls.  The density of each band 
was determined using the NIH Image J software pro-
gram,  and the density is expressed as a value relative 
to the density of the corresponding band obtained from 
the actin immunoblot.
　 Real-time PCR. RNA extraction,  reverse 
transcription-polymerase chain reaction (RT-PCR) and 
quantitative real-time PCR were performed as 
described [23,  29].  Tissues or cells were homoge-
nized,  and the total RNA was extracted using an 
RNeasy Midi Kit (Qiagen,  Chatsworth,  CA,  USA) for 
in vivo assays or an RNeasy Mini Kit (Qiagen) for in 
vitro assays,  and the samples were stored at －80℃ 
until use.  The total RNA was subjected to RT with 
poly-d (T) primers and reverse transcriptase (RTG 
T-Primed First-Strand kit; Amersham Pharmacia 
Biotech,  Piscataway,  NJ,  USA).  Quantitative real-
time PCR was used to quantify the amounts of 
TNF-α,  TGF-β1,  MCP-1 and ﬁbronectin mRNA.  
cDNA was diluted 1 : 5 with autoclaved deionized 
water,  and 5µl of the diluted cDNA was added to 
Lightcycler Mastermix,  0.5µmol/l of speciﬁc primers,  
3mmol/l MgCl2 and 2µl of Master SYBR Green 
(Roche Diagnostics,  Mannheim,  Germany).  This reac-
tion mixture was ﬁlled up to a ﬁnal volume of 15µl 
with water.  PCR was carried out in a real-time PCR 
cycler (Lightcycler; Roche Diagnostics).
　 The program was optimized and ﬁnally performed 
as: denaturation at 95℃ for 10min,  followed by 60 
cycles of ampliﬁcation for MCP-1 (95℃ for 10sec,  
68℃ for 10sec and 72℃ for 16sec),  50 cycles of 
ampliﬁcation for TNF-α and ﬁbronectin (TNF-α:  
95℃ for 10sec,  60℃ for 10sec and 72℃ for 
10sec,  ﬁbronectin: 95℃ for 10sec,  62℃ for 10sec 
and 72℃ for 8sec),  45 cycles of ampliﬁcation for 
TGF-β (95℃ for 10sec,  60℃ for 10sec and 72℃ 
for 8sec) and 40 cycles of ampliﬁcation for 18S 
rRNA (95℃ for 10sec,  68℃ for 10sec and 72℃ for 
16sec).  The temperature ramp rate was 20℃ per sec.  
At the end of each extension step,  the ﬂuorescence 
was measured to quantify the PCR products.
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　 After completion of the PCR,  we measured the 
melting curve of the product by using the temperature 
gradient from 65℃ to 95℃ at 0.2℃ per sec,  with 
continuous ﬂuorescence monitoring to produce a melt-
ing proﬁle of the primers.  The amount of PCR prod-
ucts was normalized to that of 18S rRNA to deter-
mine the relative expression ratio for the mRNA.  The 
following oligonucleotide primers speciﬁc for mouse 
TNF-α,  TGF-β1,  MCP-1,  ﬁbronectin and 18S 
rRNA were used:
TNF-α: 5ʼ-GTTCTATGGCCCAGACCCTCAC-3ʼ
(forward)
and 5ʼ-GGCACCACTAGTTGGTTGTCTTTG-3ʼ (re 
verse);
TGF-β1: 5ʼ-GTGTGGAGCAACATGTGGAACT 
CTA-3ʼ (forward)
and 5ʼ-TTGGTTCAGCCACTGCCGTA-3ʼ (reverse);
MCP-1 : 5 ʼ-AGGTCCCTGTCATGCTTCT-3 ʼ 
(forward)
and 5ʼ-CTGCTGGTGATCCTCTTGT-3ʼ (reverse);
fibronectin; 5ʼ-GCTTTGGCAGTGGTCATTTCAG 
-3ʼ (forward)
and 5ʼ-ATTCCCGAGGCATGTGCAG-3ʼ (reverse);
18S rRNA: 5ʼ-TTCTGGCCAACGGTCTAGACAA 
C-3ʼ (forward)
and 5ʼ-CCAGTGGTCTTGGTGTGCTGA-3ʼ (reverse).
　 In vitro experiments. Primary murine mesan-
gial cells (Mes13) were purchased from the ATCC 
(Rockville,  MD,  USA).  Mesangial cells were used 
between the 10th and 20th passage.  The characteris-
tics of mesangial cells were conﬁrmed by immunoreac-
tivity for actin and desmin and a lack of staining for 
factor VIII,  as described previously [30].  The cells 
were cultured in Dulbeccoʼs modiﬁed Eagleʼs medium 
(DMEM; Sigma,  St. Louis,  MO,  USA) containing 
10ｵ fetal calf serum (FCS; Cansera International,  
Etobicoke,  Ontario,  Canada),  100U/mL penicillin 
and 100µg/mL streptomycin at 37℃.  After they 
become subconﬂuent,  we starved the cells for 24h by 
incubating them in DMEM containing 0.2ｵ FCS.
　 The resulting quiescent cells were incubated with 
5.5mM normal glucose (NG),  NG with 19.5mM man-
nitol (NG/Manni),  25mM high glucose (HG) with 
PBS-DTT buﬀer (HG/N0),  HG with ONO-1301 at 
1nM (HG/O1),  10nM (HG/O10) or 100nM (HG/
O100) for 6h (for real-time PCR) or 12h (for immu-
noblotting).  We determined the concentration of man-
nitol (19.5mM) in order to set the osmotic pressure of 
the NG group (5.5mM) equivalent to that of the HG 
group (25mM).  In another set of experiments per-
formed to assess the involvement of the PGI2 (IP) 
receptor,  we incubated the quiescent Mes13 cells with 
HG with 100nM ONO-1301 in the presence of a selec-
tive PGI2 (IP) receptor antagonist CAY10449 
(Cayman Cehemical,  Ann Arbor,  MI,  USA) at a 
concentration of 0,  10 or 100nM.  The cells were then 
harvested and subjected to immunoblotting or real-time 
PCR analyses.
　 Statistical analysis. All values are expressed 
as the means ± SEM.  The results were analyzed using 
a one-way analysis of variance (ANOVA),  followed by 
Tukeyʼs post-hoc test,  when the data were paramet-
ric.  If necessary,  the data were analyzed with a non-
parametric Kruskal-Wallis test,  followed by a Steel-
Dwass multiple comparisons test.  A value of p＜0.05 
was considered signiﬁcant.  All statistical tests were 
performed using the JMP version 9 software package 
(SAS Institute,  Cary,  NC,  USA).
Results
　 Changes in blood glucose, lipids and renal 
function. The diabetic db/db mice treated with 
vehicle exhibited hyperglycemia throughout the 
experimental period.  Treatment with SR-ONO did not 
aﬀect the hyperglycemia in the diabetic mice (Table 
1).  Similarly,  SR-ONO treatment did not signiﬁ-
cantly aﬀect the plasma levels of total cholesterol,  
BUN or creatinine in the diabetic mice (Table 1).  The 
diabetic db/db mice treated with the vehicle exhibited 
higher body weights and visceral fat weights (perites-
ticular fat weight adjusted by body weight) at 8 wks 
compared to the non-diabetic mice,  and treatment with 
SR-ONO did not signiﬁcantly inﬂuence these parame-
ters in the diabetic mice (Table 1).
　 Serum levels of ONO-1301. Previous studies 
demonstrated that the subcutaneous injection of 
SR-ONO resulted in stable circulating levels of ONO-
1301 for 3 wks [12,  17,  18].  In the present study,  
the serum levels of ONO-1301 were signiﬁcantly ele-
vated in the SR-ONO-treated mice,  whereas the con-
centration of ONO-1301 was below the limit of detec-
tion in the non-diabetic mice and in the vehicle-treated 
diabetic mice (Fig.  1A).
　 Changes in creatinine clearance and urinary 
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albumin excretion. The diabetic mice treated with 
the vehicle showed a marked elevation of Ccr and 
UACR compared to the non-diabetic control mice.  
Treatment with SR-ONO did not signiﬁcantly aﬀect 
the elevation of Ccr (Fig.  1B),  but signiﬁcantly sup-
pressed the increase in the UACR compared to the 
vehicle treatment in diabetic mice (Fig.  1C).
　 Histology and morphometric analysis. The 
glomerular hypertrophy observed in the vehicle-
treated db/db mice was mildly suppressed by SR-ONO 
treatment,  and the mesangial matrix expansion 
observed in the vehicle-treated diabetic mice was also 
reduced by SR-ONO treatment (Fig.  2A-C).  A mor-
phometric analysis (Fig.  2D,  E) further conﬁrmed the 
presence of signiﬁcant inhibitory eﬀects of SR-ONO 
on these parameters.  In the diabetic mice,  tubuloint-
erstitial injuries were not evident on PAS-stained 
sections.
　 Immunohistochemical analysis of glomerular 
type IV collagen. We next examined the accumu-
lation of glomerular type IV collagen by immunoﬂuo-
rescence (Fig.  3).  The amount of type IV collagen in 
the glomeruli was increased in the vehicle-treated 
diabetic mice (Fig.  3B) compared to the non-diabetic 
mice (Fig.  3A).  Enhanced immunoreactivity in the 
diabetic mice was observed mainly in the glomerular 
and tubular basement membrane,  Bowmanʼs capsule 
and in the mesangial area.  Treatment with SR-ONO 
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Table 1　 Clinical parameters of the three treatment groups
db/m db/db (vehicle) db/db (SR-ONO)
Body weight (g) 28.4±0.4 46.1±0.8＊ 49.0±3.3＊
Peritesticular fat weight (mg/g body weight) 15.9±2.6 56.2±5.2＊ 60.5±2.2＊
Blood pressure SBP/DBP (mmHg) 122±3/76±4 121±2/74±4 117±3/72±3
Blood glucose (mg/dL) 119±2 590±5＊ 579±9＊
BUN (mg/dL) 18.0±1.4 23.0±4.0 18.1±1.8
Serum creatinine (mg/dL) 0.117±0.015 0.063±0.006＊ 0.047±0.009＊
Total cholesterol (mg/dL) 78.0±1.5 119.8±5.8＊ 122.2±3.4＊
＊p＜0.01 vs. db/m.  The values are shown as the means ± SEM.  N＝6 in each group.  BUN,  blood urea nitrogen; SR-ONO,  slow-
release form of ONO-1301; SBP/DBP,  systolic BP/diastolic BP.
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Fig. 1　 (A) The serum levels of ONO-1301 were undetectable in the non-diabetic mice and the vehicle-treated db/db mice.  In the db/db 
mice treated with SR-ONO,  a signiﬁcant elevation of the serum levels of ONO-1301 was observed.  (B) The increase in the Ccr in the 
db/db mice was not aﬀected by treatment with SR-ONO.  (C) The urinary albumin/creatinine ratio (UACR).  The increase in the UACR was 
signiﬁcantly suppressed by treatment with SR-ONO (10mg/kg,  every 3 wks) compared to the vehicle treatment.  The data obtained at the 
end of the experimental period are shown. ＊p＜0.01 vs. non-diabetic mice.  #p＜0.01 vs. diabetic mice.  n＝6 in each group.  Each col-
umn shows the means ± SE.  SR-ONO,  slow-release form of ONO-1301.
(Fig.  3C) decreased the accumulation of type IV col-
lagen in the db/db mice compared to the vehicle treat-
ment,  and these results were conﬁrmed by a quantita-
tive morphometric analysis (Fig.  3D).  We further 
evaluated the expression of type IV collagen in the 
renal cortex by performing an immunoblot analysis.  
Again,  the increases in the protein levels of type IV 
collagen in the db/db mice were signiﬁcantly prevented 
by the treatment with SR-ONO (Fig.  3E).
　 Renal levels of TGF-β and α-SMA. TGF-β1 
is a pro-ﬁbrotic factor involved in the mesangial 
matrix expansion and renal hypertrophy in diabetic 
nephropathy [31].  The present immunoblot analysis 
for TGF-β1 revealed that the levels of TGF-β1 were 
increased in the vehicle-treated diabetic mice com-
pared to the non-diabetic mice (Fig.  4A,  B).  Treatment 
with SR-ONO signiﬁcantly prevented this increase in 
the levels of TGF-β in the db/db mice compared to the 
vehicle treatment (Fig.  4A,  B).
　 In diabetic glomeruli,  the mesangial cells express 
α-SMA in association with the phenotypic alteration of 
these cells,  leading to the excessive accumulation of 
mesangial matrix.  We therefore examined the protein 
levels of α-SMA by an immunoblot analysis.  The lev-
els of α-SMA were increased in the vehicle-treated 
diabetic mice compared to the non-diabetic mice (Fig.  
4A,  C).  Treatment with SR-ONO signiﬁcantly sup-
pressed the elevation of α-SMA compared to the 
vehicle treatment (Fig.  4A,  C).
　 Monocyte/macrophage inﬁ ltration and the 
expression of MCP-1/TNF-α. We next examined 
the glomerular inﬁltration of monocytes/macrophages 
by performing an immunohistochemical study of 
F4/80.  In the vehicle-treated diabetic mice (Fig.  5B),  
the number of glomerular F4/80＋ cells was signiﬁ-
cantly increased compared to that in the non-diabetic 
mice (Fig.  5A).  Treatment with SR-ONO (Fig.  5C) 
markedly suppressed the accumulation of monocytes/
macrophages in the glomeruli compared to the vehicle 
treatment (Fig.  5D).
　 Monocytes/macrophages are recruited by the local 
expression of MCP-1.  TNF-α,  a well-known proin-
ﬂammatory cytokine,  is also involved in microinﬂam-
mation and in the pathogenesis of diabetic nephropa-
thy.  The increases in the levels of MCP-1 in the 
diabetic kidneys were signiﬁcantly suppressed by the 
treatment with SR-ONO,  as shown by the results of 
the immunoblot and real-time PCR analyses (Figs.  
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Fig. 2　 (A-C) Representative light microscopic ﬁndings 
of the glomeruli PAS staining,  original magniﬁcation ×400) 
for non-diabetic db/m (A),  diabetic db/db treated with 
vehicle (B),  and db/db mice treated with SR-ONO (C).  (D) 
The increase in the glomerular volume in the db/db mice 
was signiﬁcantly suppressed by treatment with SR-ONO.  
(E) The mesangial matrix index was deﬁned as the propor-
tion of the glomerular tuft occupied by the mesangial matrix 
area (excluding nuclei).  The increase in the mesangial 
matrix index in the db/db mice was signiﬁcantly suppressed 
by treatment with SR-ONO compared to the vehicle treat-
ment.  ＊p＜0.01 vs. non-diabetic mice.  #p＜0.01 vs. dia-
betic mice.  n＝6 in each group.  Each column shows the 
means ± SE.
5E,  F).  Similarly,  the increase in the level of TNF-α 
mRNA in the renal cortex of the db/db mice was sig-
niﬁcantly inhibited by the treatment with SR-ONO 
compared to the vehicle treatment (Fig.  5G).
　 Immunohistochemical analysis of glomerular 
oxidative stress. We next analyzed the glomerular 
accumulation of oxidative stress-related substances.  
The localization of MDA-positive areas was mainly in 
podocytes.  The glomerular accumulation of MDA was 
markedly increased in the db/db mice (Fig.  6B) com-
pared to the db/m mice (Fig.  6A).  SR-ONO treatment 
signiﬁcantly suppressed the glomerular accumulation 
of these substances (Fig.  6C),  as conﬁrmed by a 
quantitative morphometric analysis (Fig.  6D).  These 
results suggest that macrophage inﬁltration might 
cause an increased in the glomerular oxidative stress,  
leading to podocyte damage and subsequent albuminu-
ria,  and that treatment with SR-ONO eﬀectively 
suppressed this cascade.
　 Fibrotic and inﬂ ammatory protein expres-
sion in cultured mesangial cells. We performed 
in vitro experiments using mouse mesangial cells 
(Mes13) to examine the direct eﬀects of SR-ONO on 
the expression of ﬁbrotic and inﬂammatory proteins 
under the high-glucose (HG) condition.  The immunob-
lotting and real-time PCR analyses demonstrated that 
the proﬁbrotic TGF-β1 expression was markedly 
increased under the HG condition compared to the 
normal glucose condition,  and SR-ONO signiﬁcantly 
suppressed its expression in a concentration-depen-
dent manner (Fig.  7A,  B).  The HG-induced α-SMA 
expression in mesangial cells,  suggesting the altera-
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Fig. 3　 (A-D) The glomerular accumulation of type IV collagen was assessed 
by immunoﬂuorescence studies in non-diabetic db/m mice (A),  diabetic db/db 
mice treated with the vehicle (B),  and db/db mice treated with SR-ONO (C).  
(A-C) Original magniﬁcation×400.  (D) The amount of immunoreactive type IV 
collagen in the glomeruli was determined by semiquantitative scoring.  The accu-
mulation of glomerular type IV collagen in the diabetic mice was signiﬁcantly sup-
pressed by treatment with SR-ONO compared to the vehicle treatment.  (E) The 
results of the immunoblot analysis of type IV collagen relative to actin are shown.  
＊p＜0.01 vs. non-diabetic mice.  #p＜0.01 vs. vehicle-treated diabetic mice.  n＝6 
in each group.  Each column shows the means ± SE.
tion of the cellʼs phenotype into activated mesangial 
cells [32],  was signiﬁcantly suppressed by treatment 
with SR-ONO (Fig.  7C).  The increased production of 
type IV collagen and ﬁbronectin in the mesangial cells 
cultured in the HG condition was also inhibited by 
SR-ONO (Figs.  7C-F).  The increase in the MCP-1 
expression under the HG condition was also signiﬁ-
cantly prevented by SR-ONO treatment,  in a concen-
tration-dependent manner (Fig.  7G.  These ﬁndings 
suggest that SR-ONO may directly act on mesangial 
cells to inhibit the accumulation of ECM and the 
inﬁltration of macrophages.
　 Lastly,  we examined whether these therapeutic 
eﬀects of SR-ONO were mediated by the PGI2 (IP) 
receptor expressed on mesangial cells,  by using a 
selective IP receptor antagonist,  CAY10449.  The 
inhibitory eﬀects of SR-ONO on the expression of 
TGF-β1 and MCP-1 were signiﬁcantly reversed by 
treatment with CAY10449 (Fig.  8A,  B),  suggesting 
that IP receptor signaling has a crucial role in mediat-
ing the therapeutic eﬀects of SR-ONO.
Discussion
　 We demonstrated herein that the administration of 
slow-release ONO-1301MS ameliorated the glomeru-
lar injury and albuminuria in a mouse model of type 2 
diabetic nephropathy.  ONO-1301 is a synthetic pros-
tacyclin agonist possessing potent inhibitory activity 
against TXA2 synthase [9].  The therapeutic eﬀects of 
prostacyclin and its analogues have been demonstrated 
for several disease conditions,  including myocardial 
ischemia [33] and pulmonary arterial hypertension 
[34].  In addition,  beraprost sodium,  a prostacyclin 
analogue,  has been shown to have therapeutic eﬀects 
against proteinuria and glomerular injuries in both the 
streptozotocin (STZ)-induced type 1 diabetic and obese 
OLETF type 2 diabetic rat models [35,  36].  TXA2 
has been considered to be a critical mediator of the 
diabetic endothelial dysfunction,  as well as renal 
injury,  probably via its regulation of renal oxidative 
stress.  The therapeutic eﬀects of a thromboxane 
receptor antagonist,  S18886,  were reported in STZ-
induced diabetic apolipoprotein E-deﬁcient mice [37] 
and in obese Zucker type 2 diabetic rats [38].  These 
ﬁndings suggest that ONO-1301 may be a promising 
therapeutic agent for diabetic nephropathy.
　 The pathogenesis of type 2 diabetic nephropathy 
has been found to be extremely complicated.  Obesity 
and metabolic factors are apparently involved in the 
development and progression of this disease process.  
However,  in the present study,  ONO-1301 did not 
aﬀect the body weight,  visceral fat weight,  blood 
glucose or total cholesterol level of obese db/db mice.  
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Fig. 4　 The results of the immunoblot analyses of TGF-β1 and 
α-SMA.  (A) The expression levels of TGF-β1 (B) and α-SMA (C) 
were determined by immunoblotting for non-diabetic controls,  dia-
betic mice treated with vehicle and diabetic mice treated with 
SR-ONO.  The intensities relative to actin based on the densitome-
try data are shown.  The expression levels of both molecules were 
markedly increased in the vehicle-treated db/db mice compared to 
the db/m mice, and were signiﬁcantly suppressed by SR-ONO. ＊p
＜0.01 vs. non-diabetic animals.  #p＜0.01 vs. vehicle-treated dia-
betic animals.  n＝6 in each group.  Each column shows the means 
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Fig. 5　 The inﬁltration of monocytes/macrophages and the expression of MCP-1 and TNF-α.  The glomerular accumulation of F4/80＋ 
monocytes/macrophages was assessed by an immunohistochemical analysis of the non-diabetic controls (A),  diabetic mice treated with 
vehicle (B),  and diabetic mice treated with SR-ONO (C).  F4/80＋ cells were observed in the diabetic mice (arrowheads; original magniﬁ-
cation ×400).  (D) The numbers of glomerular F4/80＋ monocyte/macrophages are shown.  The accumulation of F4/80＋ monocytes/
macrophages in the diabetic mice was signiﬁcantly suppressed by the SR-ONO treatment compared to the vehicle treatment.  The expres-
sion of MCP-1 was determined by an immunoblot analysis (E) and real-time PCR (F).  (G) The expression of TNF-α was determined by 
real-time PCR.  The data are expressed as the values relative to 18S-ribosomal RNA.  The data are also expressed as values relative to 
actin for the immunoblot analyses and 18S-ribosomal RNA for the real-time PCR.  ＊p＜0.01 vs. non-diabetic animals.  #p＜0.01 vs. vehicle-
treated diabetic animals.  n＝6 in each group.  Each column shows the means ± SE.
Nonetheless,  ONO-1301 reduced the albuminuria and 
ameliorated the glomerular mesangial expansion in 
these mice.  These are the reasons why we focused on 
the direct eﬀects of ONO-1301 on glomerular injury 
in the present study.  Glomerular hyperﬁltration and 
glomerular hypertrophy,  as well as albuminuria,  are 
characteristic signs of early diabetic nephropathy.
　 An earlier study suggested that the glomerular size 
might aﬀect the rate of renal functional decline [39].  
ONO-1301 mildly prevented glomerular hypertrophy 
but not hyperﬁltration,  as indicated by the increased 
creatinine clearance,  in the diabetic db/db mice.  These 
ﬁndings are consistent with our previous report of the 
eﬀects of ONO-1301 treatment in mice with type 1 
diabetic nephropathy [17].  A clariﬁcation of the 
potential therapeutic eﬀects of SR-ONO treatment on 
glomerular hyperﬁltration at the higher dosage 
requires further investigation.
　 Mesangial cells play a critical role in the patho-
genesis of diabetic glomerular injury.  Hyperglycemia 
stimulates this type of cells to exhibit a ﬁbroblast-like 
phenotype and express α-SMA [2].  These trans-
formed cells produce excessive ECM molecule,  such 
as collagen and ﬁbronectin,  and they promote the 
replacement of the normal tissue with ﬁbrous tissue,  
leading to glomerulosclerosis.  In a previous study in 
humans,  the degree of mesangial matrix expansion 
correlated with the decrease in the glomerular capil-
lary ﬁltration surface area [40].  Beneﬁcial eﬀects of 
ONO-1301 on mesangial cells were observed in the 
present study.  ONO-1301 reduced the accumulation of 
mesangial matrix,  which was associated with a 
decreased level of renal TGF-β expression (Fig.  9).  
Such eﬀects are consistent with the previous reports 
of anti-ﬁbrotic eﬀects of ONO-1301 in experimental 
models of pulmonary ﬁbrosis and renal tubulointersti-
tial ﬁbrosis [10,  18].
　 The inﬁltration of monocytes/macrophages into 
glomeruli is also involved in the progression of dia-
betic nephropathy.  In this study,  ONO-1301 attenu-
ated the glomerular inﬁltration of monocytes/mac-
rophages in diabetic mice (Fig.  9).  This beneﬁcial 
eﬀect of ONO-1301 was associated with a reduction of 
glomerular oxidative stress (Fig.  9).  In another study,  
anti-inﬂammatory eﬀects of a prostacyclin analogue,  
beraprost sodium,  were demonstrated in a model of 
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Fig. 6　 The results of the immunohistochemical analysis of oxidative stress marker.  The 
glomerular accumulation of MDA (A-C),  a representative oxidative stress marker,  was 
assessed by an immunohistochemical analysis of non-diabetic control mice (A) and dia-
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Fig. 7　 The inhibitory eﬀects of ON-1301 on the expression of representative mediators involved in ﬁbrosis and inﬂammation in mouse 
mesangial cells cultured in normal glucose (NG) or high-glucose (HG) medium.  Immunoblotting and real-time PCR analyses demonstrated 
that the HG-induced upregulation of TGF-β protein (A) and mRNA (B),  α-SMA (C,  D),  type IV collagen (C,  E),  ﬁbronectin (F) and 
MCP-1 (G) were signiﬁcantly suppressed by ONO-1301.  The data are expressed as values relative to actin for the immunoblots and 
18S-ribosomal RNA for the real-time PCR.  ＊p＜0.01 vs. NG.  #p＜0.01 vs. HG.  n＝5 in each group.  Each column shows the means ± SE.
diabetic nephropathy,  and the eﬀects were found to be 
related to a decreased expression of glomerular inter-
cellular adhesion molecule-1 (ICAM-1) [35].  In the 
present study,  however,  ONO-1301 was shown to 
suppress the expression of MCP-1,  a chemokine that 
contributes to the recruitment of monocytes/mac-
rophages.
　 The importance of MCP-1 in the development of 
type 2 diabetic nephropathy was demonstrated in a 
study of MCP-1 knockout db/db mice [41].  Other 
studies also revealed an association between the inﬁl-
tration of monocytes/macrophages and the accumula-
tion of the mesangial matrix in models of diabetes 
[42].  Considering that MCP-1 is a target for various 
therapeutic agents (including statins and thiazolidine-
diones) associated with diabetic nephropathy,  the potent 
suppression of MCP-1 expression may be one of the 
major mechanisms by which ONO-1301 prevented the 
glomerular injuries in the present study (Fig.  9).
　 The speciﬁc signaling mechanisms by which ONO-
1301 exerts its beneﬁcial eﬀects have been studied in 
a variety of in vivo and in vitro models.  The PGI2 (IP) 
receptor plays central roles in such signaling path-
ways.  It has been demonstrated that ONO-1301 
directly interacts with the IP receptor,  and its major 
downstream eﬀects have been considered to be an 
increased level of cyclic AMP and the production of 
HGF [15,  43].  Our previous investigation showed 
that ONO-1301 suppressed the tubulointerstitial 
injury in a mouse model of unilateral ureteral obstruc-
tion,  and ONO-1301 suppressed α-SMA expression in 
cultured proximal tubular cells and maintained the 
epithelial phenotype via IP receptor signaling [18].  
Consistent with these ﬁndings,  blockade of the IP 
receptor led to the abolishment of the inhibitory 
eﬀects of ONO-1301 on TGF-β and MCP-1 expres-
sion in cultured mesangial cells in the present study.  
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Fig. 8　 The results of the qPCR analysis of the mRNA levels of TGF-β1 (A) and MCP-1 (B) in cultured mouse mesangial cells (Mes13 
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Fig. 9　 Schema for the potential therapeutic mechanisms of 
ONO-1301 against diabetic nephropathy.
This result indicates that the IP receptor on these 
cells may be essential for the therapeutic eﬀects of 
ONO-1301.
　 There are several potential limitations associated 
with the present study.  The intermittent administra-
tion of SR-ONO at a dose of 10mg/kg body weight 
resulted in a sustained elevation of circulating levels 
of ONO-1301 around the eﬀective therapeutic levels 
for several weeks,  as reported in previous studies 
using animal models of pulmonary hypertension and in 
a rat type 1 diabetes model [12,  17].  The dose of 
SR-ONO used in the present study was determined 
based on previous studies [10,  17].
　 Obata et al.  revealed that the administration of 
SR-ONO to rats at a dose of 300mg/kg led to signiﬁ-
cant hypotension,  but no such systemic eﬀects were 
observed at 100mg/kg [12].  Further investigation is 
needed to determine the therapeutic eﬀects of 
SR-ONO at the higher dosage,  since it may lead to 
greater renoprotective eﬀects in diabetic nephropathy.  
In addition,  the therapeutic eﬀects of SR-ONO were 
observed in the present study by initiating therapy 
from the early stage of diabetes,  and it is unclear 
whether it would be eﬀective at a later stage of dia-
betic nephropathy.
　 In conclusion,  we demonstrated that an intermit-
tent administration of SR-ONO eﬀectively amelio-
rated the alterations in a mouse model of type 2 dia-
betic nephropathy,  potentially by inhibiting inﬂammatory 
cell inﬁltration and oxidative stress at least partly 
through the interaction with the IP receptor,  and 
through anti-ﬁbrotic eﬀects.  We hope that our present 
study will eventually lead to the development of novel 
therapeutic strategies for patients with diabetic neph-
ropathy.
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